Highlights OptiNose, Inc.

Equities

OPTN

US68404V1008

Real-time Estimate Cboe BZX Other stock markets 08:54:48 15/05/2024 pm IST			5-day change	1st Jan Change
1.125 ^USD	-0.44%		+7.69%	-13.18%

14/05	Transcript : OptiNose, Inc., Q1 2024 Earnings Call, May 14, 2024
14/05	Earnings Flash (OPTN) OPTINOSE Posts Q1 Revenue $14.9M, vs. Street Est of $13.7M	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Earnings Flash (OPTN) OPTINOSE Posts Q1 Revenue $14.9M, vs. Street Est of $13.7M	14/05	MT
OptiNose, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05	CI
OptiNose, Inc. Provides Preliminary Unaudited Earnings Guidance for the Three-Month Period Ended March 31, 2024	09/05	CI
OptiNose, Inc. Provides Revenue Guidance for the First Quarter of 2024	25/04	CI
OptiNose, Inc. Provides Earnings Guidance for the Full Year 2025	25/04	CI
OptiNose Says US FDA Approves Xhance to Treat Chronic Rhinosinusitis	16/03	MT
OptiNose, Inc. Announces U.S. Food and Drug Administration Approved XHANCE (Fluticasone Propionate) Nasal Spray for the Treatment of Chronic Rhinosinusitis Without Nasal Polyps in Patients 18 Years of Age and Older	16/03	CI
Optinose, Inc. Provides Update on Hikma Manufacturing Agreement	15/03	CI
Earnings Flash (OPTN) OPTINOSE Posts Q4 Revenue $19.9M	07/03	MT
OptiNose, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03	CI
OptiNose, Inc. Provides Earnings Guidance for the First Quarter of 2024	07/03	CI
OptiNose, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07/03	CI
Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology	18/01	CI
Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE	06/12	CI
Earnings Flash (OPTN) OPTINOSE Posts Q3 Revenue $19.8M	09/11	MT
OptiNose, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11	CI
OptiNose, Inc. Revises Revenue Guidance for the Full Year of 2023	09/11	CI
OptiNose Raises Full-Year 2023 Xhance Net Revenue Outlook	10/23/10	MT
OptiNose, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/23/10	CI
Earnings Flash (OPTN) OPTINOSE Reports Q2 Revenue $19.5M	10/23/10	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights OptiNose, Inc.

Equities

OPTN

US68404V1008

Highlights

Filters